Go Pro
NASDAQ:STEX

Biosig Technologies Q2 2026 Earnings Report

Biosig Technologies logo
$1.04 0.00 (0.00%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$0.94 -0.11 (-10.10%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Upcoming Event
Earnings Conference Call
Biosig Technologies Q2 2026
00:00 / 00:00
Live Transcript
Follow Audio

Biosig Technologies EPS Results

Actual EPS
-$0.08
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biosig Technologies Revenue Results

Actual Revenue
$0.15 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biosig Technologies Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Monday, August 17, 2026
Conference Call Time
4:30PM ET

Biosig Technologies Earnings Headlines

Streamex Corp. Reports Second Quarter 2026 Financial Results
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Biosig Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biosig Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biosig Technologies and other key companies, straight to your email.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion. The technology is intended to integrate with existing electrophysiology lab equipment and workflows, supporting procedures such as ablations used to treat atrial fibrillation and other arrhythmias. By enhancing signal fidelity, the company aims to support procedural efficiency and clinical decision-making for electrophysiologists and hospital electrophysiology labs.

Biosig positions its product development around clinical validation and regulatory pathways common to medical device commercialization, and it targets adoption by hospitals, specialty clinics and physician groups that perform invasive cardiac electrophysiology procedures. The company pursues clinical studies and collaborations to demonstrate the clinical utility of its technology and to support broader commercialization within the medical community.

View Biosig Technologies Profile